U.S. biopharmaceutical firm Celgene will acquire Impact Biomedicines, a San Diego-based startup focusing on developing treatments for complex cancers, for up to $7 billion, according to Reuters.
The U.S. biopharmaceutical giant is interested in Impact Biomedicine's fedratinib, a kinase inhibitor that has shown promise in treating myelofibrosis, which is a complex blood cancer.
Under the deal, Celgene will pay $1.1 billion upfront for Impact Biomedicines. If the FDA approves fedratinib, Celgene will pay an additional $1.4 billion to the startup. Additionally, Celgene will make payments to Impact Biomedicine depending on sales of the drug. If fedratonib's net sales exceed $5 billion, Impact will receive $4.5 billion from Celgene.